Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma

Lenvatinib is a tyrosine kinase inhibitor (TKI) approved by the FDA for the treatment of radioiodine-refractory (RAIR) thyroid cancers. Side effects can be severe, however, and include headaches, hypertension, arterial and venous thromboembolic events, and fatalities. Cervical artery dissections (CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Groden, Phillip J., Lee, Thomas C., Bhattacharyya, Shamik, Connors, Jean, Lorch, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829091/
https://www.ncbi.nlm.nih.gov/pubmed/29527527
http://dx.doi.org/10.3389/fmed.2017.00220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829091/
https://www.ncbi.nlm.nih.gov/pubmed/29527527
http://dx.doi.org/10.3389/fmed.2017.00220

Ejemplares similares